

TUMOUR	TRIAL/AGENT: PHASE 1	KEY POINTS	PI	SC
Solid Tumour	AK104-101	Phase 1A dose escalation of AK104-101 - PD1/PDL1 and CTLA4 inhibitor for advanced solid tumours. Optional biopsy. 2 weekly IV	BM	CAH
Solid Tumour	ARX788	Her 2 positive gastric and breast patients only	BM	IN
Solid Tumour	BGB 900-101	Expansion for solid tumours with BGB 333PDL1 and BGB A317 PD1 combo for advance solid tumours optional biopsy.	BM	CAH
Solid Tumour	C-Stone Anti PDI	Any line, prior immunotherapy allowable	BM	CAH
Solid Tumour	KX-ORAX-002	Bioequivalence study of oral paclitaxel in patients treated with IV paclitaxel	ES	IN
Solid Tumour	MedImmune (D6840C00001)	Select Advanced Solid Tumour – MEDI5083 +/- DURVALUMAB	SF	PM
Gastric	TEND to upper GI cancer	Telephone or Electronic Nutrition care Delivery to upper GI cancer patients and impact on quality of life: a randomised controlled trial	TH	LH
HNSCC	BMS IDO: inhib + nivolumab	Paired biopsies, prior I-O permitted (2 slots remain)	BM	IN
Melanoma	BMS IDO inhib + nivolumab	Paired biopsies, prior I-O permitted	BM	IN
Prostate	ES414 antibody mCRPC	Continuous infusion via CADD	AA	IN
Prostate	GSK525762 + abiraterone or enzalutamide mCRPC daily oral	1 biopsy W3	AA	CB
RCC	BMS IDO: IDO inhib + Nivolumab	Paired biopsy	BM	IN
RCC	Corvus: Adenosine antag +/- PDL1 (atezolizumab)	Paired biopsies, prior I-O permitted	BM	IN
Ovarian	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD, platinum sensitive	BM	PM
Ovarian	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA WT, platinum sensitive	BM	PM
TNBC	Corvus: Adenosine antag +/- PDL1 (atezolizumab)	Paired biopsies, prior I-O permitted, only PDL1 (4 slots remain)	BM	IN
TNBC	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD	BM	PM
TNBC	T-Vec-20140299	Administration by image guided injection into liver lesion, additional liver biopsy W1, 7 & 16	BM	CAH
Colorectal with liver metastases	T-Vec-20140299	Administration by image guided injection into liver lesion, additional liver biopsy W1, 7 & 16	BM	CAH
Oesophageal & GOJ	APROC: APR246 plus 5FU/cisplatin	Platinum refractory only, <=2 lines chemo in met setting	BM	CB
PEARL	PEARL	Palliative Care Early in Advanced Lung Cancers	PP/MF	JH

STREAM CONTACT NUMBERS

Phase I	Gastrointestinal (GI)	Breast & Gynaecology	Lung and Other	Genitourinary (GU)
0474 769 510	0436 386 758	0491 299 561	0436 387 306	0436 387 664

TUMOUR	TRIAL	TRIAL/AGENT: PHASE 2/3	PI	SC
Breast	Contessa	Ph 3 Study of Tesetaxel + Capecitabine vs Capecitabine alone for HER2 negative, HR positive, Locally Advanced or Metastatic Breast Cancer, patients with prior taxane treatment	MW	LC
Ovarian	DYNAMIC	Circulating Tumour DNA	GG	KB
Breast	PROSPER - 1	PROliferation Signature in Prognosticating ER + breast cancers	MH	
Breast	PATINA	Phase III palbociclib + Anti-Her2 therapy + endocrine therapy vs Anti-Her2 + endocrine therapy post induction treatment – for HR+, HER2+ metastatic br ca	MW	LC
HNSCC- rec/met	BMS study	Open Label, Randomized, Study of Nivolumab + Ipilimumab Vs Extreme Study Regimen as a 1 st line therapy	DD	LM
NSCLC	BR.31	Double blind placebo adjuvant MEDI4736 in completely resected NSCLC	PB	LM
NSCLC	Fraction lung	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced NSCLC	BM	LT
NSCLC	GMap	Translational trial, bloods from NSCLC patients will be taken prior to receiving anti-PD-1 immunotherapy	ES	MG
NSCLC	OSCILLATE	Ph 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced NSCLC	PB	LT
Rare Cancers	Rare Cancers	A Phase II Clinical Trial Evaluating IPI and Nivo for the treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers	BM	LM
Bladder TCC	Javelin Bladder	Avelumab + supportive care vs best supportive care alone in patients who did not progress after 1st line therapy	DP	LG
mRCC	Fraction renal	Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced RCC	DP	SK
Prostate	Unison	Phase 2, Sequential Treatment Trial of Single Agent Nivolumab, then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma	DP	LD
Prostate	PROfound	Ph I/*II study of Olaparib in MCRPC patient with genetic I mutation	AA	LD
Prostate	MDV3800-06 MCRPC	Ph 2 Open-Label 2 arm st Talazoparib in DNA Repair Defects & MCRPC previous Taxane-Based Chemotherapy and Progressed on abi or enza	AA	LD
Prostate	TheraP	randomised, phase 2 trial of Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer	AA	LG
Prostate	IPATential	Ph III rand trial of abi +/- ipatasertib placebo controlled in asymptomatic or mildly symptomatic MCRPC	DP	LG
Prostate	ICE-PAC	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC)	AA	LG
Prostate	EH prostate biology	Studies of prostate cancer biology	AA	NN
Renal	Checkmate 9KD	Phase 2, Nivolumab in combination with either Rucaparid, Docetaxel, or Enzaltamide in men with Castration-resistant Metastatic Prostate Cancer	AA	SK
Renal	Keypad	Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601)	DP	SK
Adj CRC	ASCOLT	Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers	AS	CP
Adj Gastrooes	Checkmate G/O	Nivolumab or placebo in patients with resected lower esophageal or GOJ	AS	CP
Gastric	Blu-285-1303	Open-label, Randomized, Ph 3 Study of BLU-285 vs Regorafenib in Patients with locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)	ES	FM
Gastric	BGB-290-303	Ph 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy	AS	FM
Colorectal	Liberate	A study evaluating liquid biopsies to profile metastatic colorectal cancer	ES	CP
Colorectal	Monarcc	Randomized Ph 2 Study of Panitumumab monotherapy and panitumumab plus fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer	ES	FM
CRC Stage II	Dynamic	Circulating tumour DNA analysis informing adjuvant chemotherapy	MH	CP
GI NEC	NABNEC	Randomised Ph II: nab-paclitaxel + carboplatin as 1 st line treatment	BM	KC
mBRAF mCRC	ARRAY (BEACON)	Open-Label 3-arm study; Encorafenib + Cetuxomab Bimetinib vs Irinotecan/Cetuximab or FOLFIRI/Cetuximab	AS	IA
Met Gastrooes	INTEGRATE II	Double-blind Placebo-controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer	AS	KC
Pancreas	ASPEN	Management of Sporadic Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤ 2 cm	ES	
Pancreas	Dan Croagh	Panitumumab as second line therapy for advance pancreatic ductal adenocarcinoma with wild-type RAS gene. A pilot activity study	MH	
Pancreas	Halo	RDB placebo-contr PEGylated recombinant hyaluronidase (PEGPH20) + nab-Paclitaxel + gemcitabine in hyaluron-high 1 st L	MH	KC
Rectal	AveRec	Neo Adjuvant Rectal	ES	FM